



- 777 Echovirus Type 13 United States, 2001
- 780 Influence of Homicide on Racial Disparity in Life Expectancy — United States, 1998
- 783 Notices to Readers

# Echovirus Type 13 — United States, 2001

Echoviruses constitute one of the major groups of the genus *Enterovirus* and are associated with illnesses including aseptic meningitis, nonspecific rashes, encephalitis, and myositis (1). Echovirus 13 is an enterovirus that rarely has been detected in the United States, accounting for only 65 of approximately 45,000 enterovirus isolates reported to CDC during 1970–2000. No associated outbreaks have been reported in this country. As of June 2001, eight state public health laboratories and one private laboratory had reported an increased number of echovirus 13 isolates to CDC, most associated with aseptic meningitis. This report summarizes echovirus 13 activity in the United States and highlights the investigation of aseptic meningitis outbreaks in Louisiana, Mississippi, Montana, and Tennessee. Echovirus 13 should be considered in the differential diagnosis of persons with aseptic meningitis.

CDC's National Enterovirus Surveillance System (NESS) relies on voluntary reporting of enterovirus isolates by serotype from state public health laboratories (2). Aseptic meningitis was removed as a nationally notifiable disease in 1995, and no uniform nationally recognized case definition exists for this condition (3). Cases of aseptic meningitis described in this report represent physician diagnoses based on clinical presentation and laboratory findings.

As of August 14, 2001, echovirus 13 has been isolated in specimens from 76 patients in 13 states (Tennessee [26], Mississippi [10], Louisiana [nine], Florida [eight], Texas [six], California [six], Kentucky [three], Ohio [two], Montana [two], and Georgia, Illinois, Indiana, and North Carolina [one each]). Of 76 isolates tested, 51 (67%) were from cerebrospinal fluid (CSF) and 12 (16%) from stool or rectal swabs. The source specimens for these isolates were collected during March–June 2001.

Of the 76 patients, 47 (62%) were male. The patients ranged in age from 2 weeks to 29 years (median age: 7 months). Most (73 [96%]) were aged <15 years, 41 (54%) were infants aged <1 year, and 29 (38%) were aged <3 months.

Clinical diagnoses were reported for 52 (68%) of the 76 patients and included aseptic meningitis (50 patients), febrile illness (one), and diarrhea (one). Of 50 isolates from patients with a diagnosis of aseptic meningitis, 45 were associated with outbreaks of aseptic meningitis in four states (26 from Tennessee, nine from Mississippi, eight from Louisiana, and two from Montana) during April–July 2001.

**Louisiana.** In June, 27 cases of aseptic meningitis among patients admitted to one hospital during May 22–June 20 were reported to the Louisiana Office of Public Health (Table 1), representing a nine-fold increase in the number of aseptic meningitis

#### Echovirus Type 13 — Continued

	Lou (n:	isiana =27)	Miss (n:	issippi =56)	Mon (n=	itana :23)
Characteristic	No.	(%)	No.	(%)	No.	(%)
Sex						
Male	18	(67)	26	(46)	13	(56)
Female	9	(33)	30	(54)	10	(44)
Age group						
<u>&lt;</u> 3 mos	9	(33)	11	(20)	6	(26)
4–11 mos	0		3	(5)	2	(9)
1–14 yrs	14	(52)	33	(59)	14	(61)
≥15 yrs	4	(15)	9	(16)	1	(4)
Median age (range)	7 yrs (3 w	rks–43 yrs)	6 yrs (3 d	lays–48 yrs)	7 yrs (8 d	days–23 yrs)
Enterovirus isolates*						
Echovirus 13	ξ	8		3		2
Total	S	9		9		3

TABLE 1. Number of persons with aseptic meningitis	, by selected characteristics
- Louisiana, Mississippi, and Montana, 2001	

\* Echovirus 13 was isolated from cerebrospinal fluid (CSF) for all isolates in the Louisiana and Mississippi outbreaks and from rectal swabs for both isolates from Montana. Echovirus 6 was isolated from the CSF of one patient from the Louisiana outbreak. Eight CSF specimens from the Mississippi outbreak tested positive for an enterovirus in a polymerase chain reaction with pan-enterovirus primers. Echovirus 13 was cultured from two of these specimens. Echovirus 25 was isolated from a throat swab of one patient from Montana.

hospitalizations over the same period during 2000. All of the patients resided in three parishes (i.e., counties) in the southeastern part of the state. Of the 27 cases, 20 (74%) occurred in the same parish (hospitalization rate: 20 per 100,000 population). Reported clinical symptoms included fever (94%), headache (77%), vomiting (77%), stiff neck (50%), and photophobia (23%).

**Mississippi**. During May 5–July 31, 56 cases of aseptic meningitis were reported to the Mississippi State Department of Health from one regional medical center (Table 1). Of the 56 patients, 41 (73%) resided in a county adjacent to the Louisiana parish that accounted for most of the cases in Louisiana. The hospitalization rate for this Mississippi county was 111 per 100,000 population. Reported clinical symptoms included fever (75%), headache (70%), vomiting (55%), nausea (52%), and stiff neck (20%).

**Montana**. During June 8–July 11, 23 cases of aseptic meningitis were reported to the Montana Department of Public Health and Human Services (MDPHHS) from a single county in the southeastern part of the state (hospitalization rate: 181 per 100,000 population) (Table 1). Eighteen additional cases of aseptic meningitis reported from a neighboring county since early July are being investigated by MDPHHS.

**Tennessee**. An outbreak of aseptic meningitis involving approximately 250 persons admitted to a hospital in Tennessee since April 2001 is being investigated by the Tennessee State Health Department. Echovirus 13 has been confirmed as the etiologic agent for 33 of 75 cases.

#### Echovirus Type 13 — Continued

Reported by: N Krishna, MS, M Little, MPH, R Ratard, MD, Louisiana Office of Public Health. M Currier, MD, S Hand, Mississippi State Dept of Health. J Murphy, Montana Dept of Public Health and Human Svcs; S Zanto, Montana Public Health Laboratory; C Taft, P Schwaiger, Big Horn County Health Dept, Hardin, Montana. T Jones, MD, Tennessee State Health Dept; J Hindman, Tennessee State Public Health Laboratory; S Buckingham, MD, G Grandberry, LeBonheur Hospital, Memphis, Tennessee. MA Patterson, W Sessions, Texas Dept of Health Laboratory. P Colarusso, MSH, R Melear, MHA, Bur of Laboratories, Florida Dept of Health. D Schnurr, PhD, California Dept of Health Svcs; J Giesick, San Diego Public Health Dept. P Brantley, North Carolina Public Health Laboratory. J Dunn, PhD, ARUP Laboratories, Salt Lake City, Utah. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; and EIS officers, CDC.

**Editorial Note**: This is the first report of widespread circulation of echovirus 13 and of outbreaks associated with this enterovirus in the United States. Increased echovirus 13 activity also was reported in Europe during 2000 when echovirus 13 was associated for the first time with outbreaks of aseptic meningitis in England, Wales, and Germany (4,5).

Clinical manifestations of enterovirus infections are protean, ranging from asymptomatic carriage to life-threatening illness (6). Because echovirus 13 rarely has been isolated, the spectrum of disease associated with this virus has not been well established. Conditions previously associated with echovirus 13 are typical of enterovirus infections (6) and include asymptomatic carriage (6), mild febrile illness (7), aseptic meningitis (4,5,8,9), respiratory diseases (e.g., coryza, pharyngitis, bronchitis, and bronchiolitis [7,9]), poliomyelitis-like illness (8), diarrhea with fever (7,9), rash (7,9), encephalitis (9), and enteroviral sepsis (9). Aseptic meningitis is the predominant illness that has been associated with the current echovirus 13 activity in the United States and with echovirus activity reported in Europe in 2000. However, patients with meningitis are more likely be tested for enteroviruses than are patients with milder illnesses.

In temperate climates, enteroviruses demonstrate a marked seasonality, with widespread circulation during summer and fall. A typical enterovirus season in the United States lasts from June through October (9). In 2001, the first isolations of echovirus 13 in the United States were reported in March. The reported outbreaks of aseptic meningitis associated with this serotype started early in the enterovirus season.

The age distribution of patients with echovirus 13 isolates and of the other cases involved in the three aseptic meningitis outbreaks indicates that young children are at highest risk for infection. A similar age distribution was observed during the aseptic meningitis outbreak associated with echovirus 13 in Germany in 2000 (5), but the outbreaks in England and Wales predominantly affected older children (4).

In addition to echovirus 13, other enterovirus serotypes have been identified in these outbreaks of aseptic meningitis. The isolation of several enteroviruses in community outbreaks is not unusual because numerous serotypes commonly co-circulate. Predominant enterovirus serotypes tend to change over time (10). In the United States, the serotypes most commonly reported to NESS were echoviruses 30, 6, and 7 in 1997, echoviruses 30, 9, and 11 in 1998, and echoviruses 11, 16, and 9 in 1999 (2). Although the clinical spectrum of diseases associated with various enterovirus serotypes overlap, some manifestations of enterovirus infection are associated commonly with certain serotypes (i.e., aseptic meningitis and echovirus 30, hand-foot-and-mouth disease and coxsackievirus A16, and acute hemorrhagic conjunctivitis and enterovirus 70 and coxsackievirus A24) (6).

# Echovirus Type 13 — Continued

Enterovirus surveillance is important for understanding circulation patterns of these viruses in the United States. In addition, this information may be helpful for evaluating potential antienterovirus drugs and in understanding the links of enteroviruses with disease. More information is needed to clarify the epidemiologic characteristics and to define better the clinical spectrum of associated diseases.

No specific prevention or control measures are available for nonpolio enteroviruses, including echovirus 13. Adherence to good hygienic practices, such as frequent and thorough hand washing (especially after diaper changes), disinfection of contaminated surfaces by household cleaners (e.g., diluted bleach solution), and avoidance of sharing utensils and drinking containers may be effective in reducing the spread of infection.

# References

- 1. Modlin JF. Update on enterovirus infection in infants and children. Adv Pediatr Infect Dis 1996;12:161.
- 2. CDC. Enterovirus surveillance-United States, 1997-1999. MMWR 2000;49:913-6.
- 3. CDC. Summary of notifiable diseases, United States, 1994. MMWR 1994;43:1-8.
- 4. Communicable Disease Surveillance Centre. Viral meningitis associated with increase in echovirus type 13. Commun Dis Rep CDR Wkly 2000;10:277,280.
- Twisselmann B. Cluster of cases of viral meningitis caused by echovirus type 13 in Germany. Eurosurveillance Weekly 2000;4. Available at <a href="http://www.eurosurv.org/2000/pfp/001005\_pfp.htm">http://www.eurosurv.org/2000/pfp/001005\_pfp.htm</a>. Accessed September 2001.
- Melnick J. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields BN, Knippe DM, Howley PM, et al, eds. Fields Virology. 3rd ed. Philadelphia, Pennsylvania: Lippincott-Raven Publishers, 1996.
- 7. Hooft C, Nihoul E, Labmert Y, Valcke R. Clinical findings during an echovirus type 13 endemic infection. Helvetica Pediatrica Acta 1963;3:231–9.
- 8. Hammon WMcD, Yohn DS, Pavia RA, Sather GE. Echovirus type 13: epidemiological and clinical associations. Amer J Trop Med Hyg 1961;10:62–6.
- 9. Moore M. Enteroviral disease in the United States, 1970-1979. J Infect Dis 1982;146:103-8.
- 10. Strikas RA, Anderson LJ, Parker RA. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970–1983. J Infect Dis 1986;153:346–51.

# Influence of Homicide on Racial Disparity in Life Expectancy — United States, 1998

Life expectancy (LE) is an important indicator of the health of populations. Since the early 1900s, when estimates of LE began to be tabulated in the United States, the LE of blacks has been lower than that of whites (1). Homicide, which disproportionately affects blacks, particularly young males, contributes to this difference in LE. To examine the associations between homicide, LE, and race, CDC analyzed 1998 mortality files from the National Center for Health Statistics (NCHS). This report summarizes the results of that analysis, which indicate, that in 1998, the LE for blacks was approximately 6 years shorter than for whites and that, after heart disease and cancer, homicide was the next largest contributor to the 6-year discrepancy. Violence prevention strategies (e.g., programs for youth offenders) have been implemented for the general population. More research is needed to determine an approach to target the male black population and to reduce LE disparity.

Influence of Homicide on Racial Disparity - Continued

NCHS mortality files for 1998 (2) and the multiple-decrement life table (3) were used to examine differences between whites and blacks. These methods were used to partition the contribution to LE at birth by selected causes of death using the *International Classification of Diseases, Ninth Revision, (ICD-9)* codes\* for the four major race-sex groups (black-males, black-females, white-males, white-females) in the United States. The contribution in years for each cause of death to the black/white differential and statistical tests of difference (Z-scores) were determined using Survival software (4), with whites as the referent group. Causes of death used were based on the leading causes of death in 1998 for the total population and for both racial populations. Other causes of death were categorized as "all other causes."

In the United States during 1998, whites lived 6.2 years longer than blacks. Among the leading causes of death that contributed to the difference were heart disease (1.7 years; 27.4%), cancer (1.2 years; 19.4%), homicide (0.6 years; 9.7%), stroke (0.5 years; 8.1%), and "all other causes" (1.9 years; 30.6%). The LE differential was 6.4 years for males and 4.4 years for females. Among males, some of the leading causes of death that contributed to the LE differential were heart disease (1.2 years; 19.0%), cancer (1.0 years; 15.6%), and homicide (0.9 years; 14.1%) (Figure 1), and among females were

\*Codes 042–044; 140–208; 390–398, 402, 404–429; 430–438; 760–779; E950–E959; E810–E825, E958.5, E988.5; E960–E978.





- \* Above zero indicates greater LE among whites than blacks; below zero indicates greater LE among blacks than whites.
- <sup>†</sup> International Classification of Diseases, Ninth Revision, codes 042–044; 140–208; 390–398, 402, 404–429; 430–438; 760–779; E950–E959; E810–E825, E958.5, E988.5; E960–E978.
- <sup>§</sup> Conditions that occur during the perinatal period include birth trauma, birth asphyxia, ectopic pregnancy, and maternal death.

Source: National Center for Health Statistics mortality data.

### Influence of Homicide on Racial Disparity — Continued

heart disease (1.2 years; 27.3%), cancer (0.5 years; 11.4%), and perinatal disease (e.g., birth trauma, birth asphyxia, ectopic pregnancy, and maternal death) (0.4 years; 9.1%). Stroke and human immunodeficiency virus (HIV) accounted for 0.3 years (6.8%) and 0.3 years (6.8%), respectively, of the LE differential among females and 0.4 years (6.3%) and 0.6 years (9.4%), respectively, among males. Homicide among black females contributed 0.2 years (4.5%) to the LE differential (Figure 1).

Reported by: L Potter, PhD, Children's Safety Network, Education Development Center, Inc., Boston, Massachusetts. Etiology and Surveillance Br, Div of Violence Prevention, Office of Statistics and Programming, National Center for Injury Prevention and Control; National Center for Health Statistics; and an EIS Officer, CDC.

**Editorial Note**: The findings in this report document racial disparities in LE, which were attributable mainly to blacks having a shorter LE than whites for each examined cause of death (except suicide). For the total U.S. population in 1998, homicide ranked 13th among causes of death (5), accounting for <1% of all deaths. However, homicide accounted for approximately 10% of the LE differential. This finding suggests that causes of death that rank low for the total population may be important targets to address in attempting to eliminate the LE gap between these populations.

During 1985, the U.S. Department of Health and Human Services conducted the first analyses using health indicators that documented the health status of minority populations and found that approximately 60,000 excess deaths (i.e., the difference between the number of deaths observed in a racial/ethnic group and the number of deaths that would have occurred in that group if it had the same death rate as the non-Hispanic white population) occurred among blacks each year in the United States (6). Health disparities between blacks and the general population have been attributed to less access to health care and to health-care coverage. Risk factors for violence include living at or below the poverty level, living in single parent households, and having poor academic performance and/or exposure to neighborhood violence (e.g., gangs) (7).

The 1998 publication of *The Initiative to Eliminate Racial and Ethnic Disparities in Health* indicated a commitment to eliminating longstanding racial/ethnic disparities in health status by 2010. The initiative focuses on six key areas of health that disproportionately affect multiple racial/ethnic minority groups at all ages (8): infant mortality, cancer screening and management, cardiovascular disease, diabetes, HIV, and vaccination coverage. The findings in this report are consistent with previous findings that show homicide to be a leading contributor to the difference in LE between blacks and whites (9) and underscore the need to include homicide among the key areas.

The findings in this report are subject to at least three limitations. First, incorrect diagnoses or errors can result in inaccuracies in death records. Second, although approximately 99% of deaths in the United States are reported systematically (5), denominator data (population estimates) that refer to race or color may be inaccurate (5). Third, several assumptions (e.g., that life expectancy is aged 85 years) that could be technically flawed were made in constructing the life table model in this analysis (3).

Preventing homicide requires integrated approaches from multiple disciplines, including criminal justice, education, social services, community advocacy, and public health. Strategies for preventing violence among youth (e.g., social-cognitive, mentoring, and family-based approaches) have been described in *Best Practices to Prevent Violence by Children and Adolescents: A Sourcebook for Community Action* (10) and in

# Influence of Homicide on Racial Disparity — Continued

the *Surgeon General's Report on Youth Violence* (7). These prevention programs and strategies could be implemented by educators, public health practitioners, and law enforcement agencies to target black males. Reducing the racial LE differential in homicide will improve the health of blacks in the United States and thus reduce racial disparities in health.

# References

- National Center for Health Statistics. Life expectancy at birth, by race and sex, selected years 1929–97. Available at <a href="http://www/cdc/nchs/fastats/pdf/47\_28t12.pdf">http://www/cdc/nchs/fastats/pdf/47\_28t12.pdf</a>>. Accessed September 2001.
- 2. US Department of Health and Human Services, National Center for Health Statistics. Vital statistics mortality data, underlying cause death, 1998. [Machine-readable public-use data tapes]. Hyattsville, Maryland: US Department of Health and Human Services, CDC, National Center for Health Statistics, 2001.
- 3. Arriaga EE. Measuring and explaining the change in life expectancies. Demography 1984;21:83–96.
- 4. Smith DP. Survival program 4.1, and users' guide. Austin, Texas: University of Texas School of Public Health, 1995.
- Murphy SL. Deaths: final data for 1998. Monthly vital statistics report; vol. 48, no. 11. Hyattsville, Maryland: US Department of Health and Human Services, CDC, National Center for Health Statistics, 2000.
- US Department of Health and Human Services. Report of the Secretary's Task Force on Black and Minority Health. Bethesda, Maryland: US Department of Health and Human Services, August 1985.
- 7. US Department of Health and Human Services. Youth violence: a report of the Surgeon General. Rockville, Maryland: US Department of Health and Human Services, CDC, National Center for Injury Prevention and Control; Substance Abuse and Mental Health Services Administration, Center for Mental Health Services; and National Institutes of Health, National Institute of Mental Health, 2000. Available at <http:// www.surgeongeneral.gov/library/youthviolence>. Accessed September 2001.
- 8. US Department of Health and Human Services. Race and health initiative. Available at <a href="http://raceandhealth.hhs.gov">http://raceandhealth.hhs.gov</a>. Accessed September 2001.
- 9. Kochanek KD, Maurer JD, Rosenberg HM. Why did black life expectancy decline from 1984 through 1989 in the United States? Am J Public Health 1994;84:938–44.
- Thornton TN, Craft CA, Dahlberg LL, Lynch BS, Bear K. Best practices to prevent violence by children and adolescents: a sourcebook for community action. Atlanta, Georgia: US Department of Health and Human Services, CDC, National Center for Injury Prevention and Control, 2000.

# Notice to Readers

# **Decreased Availability of Pneumococcal Conjugate Vaccine**

In February 2000, Prevnar<sup>™</sup>, the new 7-valent pneumococcal conjugate vaccine (PCV7) marketed by Wyeth Lederle Vaccines (Pearl River, New York) was licensed for use among infants and young children. CDC recommends this vaccine for all children aged <2 years and for children aged 2–5 years who are at increased risk for pneumococcal disease (e.g., children with sickle cell disease or anatomic asplenia, chronic illness,

## Notice to Readers — Continued

or who are immunosuppressed, including those with human immunodeficiency virus infection) (1). In August 2001, deliveries of Prevnar<sup>™</sup> were delayed resulting in shortages for some health-care providers and health departments. Although the manufacturer projects shipping sufficient vaccine to meet needs throughout the remainder of 2001 and has sufficient manufacturing capacity to meet U.S. demand, health-care providers may continue to experience temporary shortages as supplies are replenished. In the meantime, CDC recommends that all providers defer the vaccination of children aged >2 years except those aged 2–5 years who are at increased risk for pneumococcal disease (see previous examples) (1). Providers should give highest priority to vaccinating all infants aged <12 months and children aged 1–5 years at increased risk. Catch-up vaccinations for healthy children aged 1–2 years and booster doses for healthy children who have completed the primary series may be deferred. Records should be kept so that the deferred vaccinations can be given when vaccine becomes available.

## Reference

 CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(no. RR-9).

# Notice to Readers

# Publication of Health, United States, 2001 with Urban and Rural Health Chartbook

CDC has published *Health, United States, 2001 with Urban and Rural Health Chartbook*, the 25th edition of the annual report on the nation's health. This report includes 148 trend tables organized around four broad subject areas: health status and determinants, health-care use, health-care resources, and health-care expenditures. Disparities in health by race/ethnicity and socioeconomic status are presented in several tables.

This year's report also includes the *Urban and Rural Health Chartbook*. Communities at different urbanization levels differ in their demographic, environmental, economic, and social characteristics, and these characteristics influence the magnitude and types of health problems that communities face. The chartbook presents population characteristics, health risk factors, health status indicators, and health-care access measures for residents of counties grouped by five urbanization levels (from the most urban to the most rural). Of U.S. residents examined, those who have the best health measures are residents of fringe counties of large metropolitan areas. In comparison, the urbanization level associated with adverse health measures is less consistent. Residents of the most rural counties fare worst on some measures (e.g., motor vehicle traffic-related injury mortality) and residents of the most urban counties fare worst on other measures (e.g., homicide).

Additional information about the report is available at <http://www.cdc.gov/nchs> (click on "Top 10 Links" to locate "Health, United States"). Print copies may be purchased from the Government Printing Office, telephone: (202) 512-1800; website: <http:// bookstore.gpo.gov/index.html>.

Notice to Readers — Continued

# Notice to Readers

# Satellite Broadcast on Immunization

Immunization Update 2001, a live interactive satellite broadcast, will be held Thursday, September 20, 2001, from 9–11:30 a.m. eastern daylight time with a repeat broadcast from 12–2:30 p.m. This broadcast will provide up-to-date information on the changing field of immunization. Topics include pneumococcal conjugate vaccine; influenza vaccine (including vaccine supply and recommendations for the 2001–02 influenza season); national shortage of tetanus and diphtheria toxoids; meningococcal vaccine; hepatitis B vaccine for adolescents; global polio eradication; and recent vaccine safety issues. Both broadcasts will feature a question and answer session in which participants nationwide can interact with the course instructors via toll-free telephone lines. Continuing education credits will be offered for a variety of professions based on 2.5 hours of instruction.

This broadcast has been designed for physicians, nurses, physician assistants, nurse practitioners, pharmacists, medical students, and others who provide immunizations and counsel patients about immunization. Online registration information is available at <a href="http://www.phppo.cdc.gov/phtnonline/">http://www.phppo.cdc.gov/phtnonline/</a> or by fax, telephone (888) 232-3299 or (877) 232-1010 and request document number 130024 (for sites) or number 130021 (for individual registration). Questions about the broadcast should be directed to Craig Wilkins, telephone (404) 639-8799, or email ckw4@cdc.gov. For questions about registration, call (800) 418-7246 (800 41-[TRAIN]).

786



### FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending September 8, 2001, with historical data

- \* No measles cases were reported for the current 4-week period yielding a ratio for week 36 of zero (0).
- <sup>†</sup> Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

		Cum. 2001		Cum. 2001
Anthrax		-	Poliomyelitis, paralytic	-
Brucellosis <sup>†</sup>		55	Psittacosis <sup>†</sup>	9
Cholera		3	Qfever <sup>†</sup>	16
Cyclosporiasis	s <sup>†</sup>	112	Rabies, human	1
Diphtheria		1 1	Rocky Mountain spotted fever (RMSF)	336
Ehrlichiosis:	human granulocytic (HGE)†	130	Rubella, congenital syndrome	-
	human monocytic (HME) <sup>†</sup>	56	Streptococcal disease, invasive, group A	2.632
Encephalitis:	California serogroup viral <sup>†</sup>	28	Streptococcal toxic-shock syndrome <sup>†</sup>	44
	eastern equine <sup>†</sup>	4	Syphilis, congenital <sup>1</sup>	164
	St. Louis <sup>†</sup>	1 1	Tetanus	21
	western equine <sup>†</sup>	-	Toxic-shock syndrome	84
Hansen diseas	se (leprosv) <sup>†</sup>	54	Trichinosis	15
Hantavirus pu	Imonary syndrome <sup>†</sup>	5	Tularemia <sup>†</sup>	73
Hemolvtic ure	mic syndrome, postdiarrheal <sup>†</sup>	82	Typhoid fever	182
HIV infection.	pediatric <sup>†§</sup>	131	Yellowfever	-
Plague	F	2		

# TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending September 8, 2001 (36th Week)\*

- No reported cases. \*Incidence data for reporting year 2001 are provisonal and cumulative (year-to-date).

<sup>5</sup> Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV,

STD, and TB Prevention (NCHSTP). Last update August 28, 2001. <sup>1</sup>Updated from reports to the Division of STD Prevention, NCHSTP.

								Escherichia	<i>coli</i> 0157:H	7†
	All	DS Cum	Chlan	nydia <sup>s</sup>	Cryptos	oridiosis	NET	NETSS PHL		LIS
<b>Reporting Area</b>	2001	2000	2001	2000	2001	2000	2001	2000	2001	2000
UNITED STATES	25,869	26,230	463,660	474,745	1,586	1,661	1,695	3,060	1,343	2,644
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	996 26 27 11 541 72 319	1,418 25 25 27 889 61 391	15,248 668 809 418 6,857 2,005 4,491	16,041 985 708 367 6,754 1,764 5,463	74 11 25 27 3 4	89 13 13 19 28 2 14	167 23 24 11 85 9 15	274 19 26 27 130 11 61	157 22 21 5 77 7 25	296 25 31 29 133 12 66
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	5,634 697 2,742 1,194 1,001	5,811 607 3,135 1,153 916	51,772 9,131 20,641 8,099 13,901	44,148 1,042 18,176 7,941 16,989	173 68 68 7 30	241 63 128 12 38	130 91 8 31 N	311 192 19 100 N	122 85 8 29	219 39 14 98 68
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	1,922 367 225 882 328 120	2,457 388 250 1,364 331 124	70,135 13,962 9,605 18,342 20,349 7,877	81,853 21,362 8,991 22,904 17,458 11,138	534 115 49 1 117 252	499 74 32 70 64 259	412 106 52 100 63 91	750 159 87 153 92 259	282 84 32 80 50 36	561 166 69 120 77 129
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. S. Dak. Nebr. Kans.	571 104 63 271 2 19 49 63	612 115 65 285 2 6 43 96	23,187 4,469 1,858 9,007 599 1,225 2,112 3,917	26,729 5,453 3,710 9,070 625 1,243 2,516 4,112	221 99 62 28 7 6 18 18	174 21 50 22 9 12 51 9	265 92 56 34 12 25 32 14	434 102 127 86 14 35 50 20	233 98 39 49 21 19 - 7	443 136 113 79 17 43 43 12
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	8,247 185 1,089 591 673 58 574 500 935 3,642	7,194 131 842 499 461 42 431 530 873 3,385	88,216 1,912 7,760 1,869 12,738 1,544 14,059 7,990 17,522 22,822	89,408 1,975 9,462 2,135 10,852 1,463 15,431 6,311 19,146 22,633	212 29 10 15 2 19 - 78 57	260 5 9 7 12 3 19 - 100 105	152 3 14 - 39 35 7 20 25	239 1 22 - 49 12 53 16 35 51	99 4 1 30 6 26 9 13 10	226 1 U 48 7 56 13 36 64
E.S. CENTRAL Ky. Tenn. Ala. Miss.	1,279 245 408 308 318	1,295 146 531 337 281	32,686 6,134 9,857 8,841 7,854	34,747 5,399 9,764 11,092 8,492	33 3 10 11 9	37 5 9 12 11	86 41 26 12 7	95 28 42 6 19	79 39 30 6 4	83 25 42 7 9
W.S. CENTRAL Ark. La. Okla. Tex.	2,836 144 602 172 1,918	2,667 126 443 219 1,879	69,172 4,940 11,314 7,147 45,771	71,555 4,588 12,811 6,014 48,142	22 5 7 8 2	93 8 10 9 66	45 7 3 18 17	194 50 13 13 118	59 24 20 15	235 34 38 11 152
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	955 14 17 2 197 84 395 84 162	1,006 10 7 239 107 318 97 212	26,696 1,349 1,211 576 5,284 4,104 9,684 1,454 3,034	27,226 1,016 1,255 539 8,050 3,366 8,758 1,569 2,673	106 8 12 29 18 6 27 4	85 8 6 5 36 9 8 10 3	188 11 38 7 69 10 20 22 11	292 26 45 13 110 15 36 37 10	100 - 1 54 8 12 24 1	217 - 28 9 78 14 27 51 10
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	3,429 371 134 2,871 15 38	3,770 332 113 3,224 15 86	86,548 9,300 3,212 69,676 1,841 2,519	83,038 8,933 4,688 65,286 1,692 2,439	211 37 24 146 1 3	183 U 13 170 -	250 65 40 129 4 12	471 141 102 190 25 13	212 62 27 119 4	364 161 95 95 3 10
Guam P.R. V.I. Amer. Samoa C.N.M.I.	10 816 2 - -	13 759 25 -	- 1,764 53 U 85	341 U U U U	- - - U	- - U U	N 1 - U	N 6 - U U		U U U U

 TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending September 8, 2001, and September 9, 2000 (36th Week)\*

 N: Not notifiable.
 U: Unavailable.
 -: No reported cases.
 C.N.M.I.: Commonwealth of Northern Mariana Islands.

 \*Incidence data for reporting year 2001 are provisonal and cumulative (year-to-date).
 Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

 \* Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

 \* Chamydia refers to genital infections caused by *C. trachomatis.* 

 \* Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update August 28, 2001.

	Gono	rrhea	Hepatit Non-A, I	tis C; Non-B	Legione	llosis	Listeriosis	Lyme Disease	
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Legionellosis Cum. Cum. 2001 2000		Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	213,146	241,110	2,344	2,245	635	680	308	7,130	11,321
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	4,283 79 107 48 2,089 526 1,434	4,571 60 74 44 1,843 429 2,121	14 - 6 8 -	22 2 4 11 5	35 5 8 4 9 2 7	39 2 3 15 3 14	32 2 2 16 1 11	2,168 88 7 472 267 1,334	3,457 41 26 999 213 2,178
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	25,925 5,537 8,627 4,983 6,778	25,626 4,817 7,744 5,076 7,989	981 42 - 896 43	499 26 - 438 35	130 39 13 7 71	184 47 27 17 93	49 20 8 10 11	3,561 1,978 2 448 1,133	5,955 2,264 154 2,170 1,367
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	37,698 7,674 4,047 11,555 11,646 2,776	48,950 13,035 4,224 14,378 12,519 4,794	123 8 1 11 103	175 8 17 150	155 83 14 - 36 22	181 71 27 24 31 28	35 11 4 1 17 2	391 95 16 1 279	678 47 19 33 21 558
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	9,852 1,445 428 5,364 19 188 700	11,869 2,193 826 5,770 51 198 985	482 7 465 - 3	404 5 1 388 - - 3	42 9 6 17 1 3 5	44 3 11 21 - 2 3	11 - 1 6 - - 1	262 215 25 17 - - 3	184 100 23 43 1 - 3
Kans.	1,708	1,846	7	7	1	4	3	2	14
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	54,612 1,122 4,277 1,714 7,611 423 11,483 5,465 9,580 12,937	63,088 1,150 6,455 1,687 6,856 454 12,721 5,805 12,216 15,744	81 - - 9 16 5 - 37	68 2 9 3 13 13 1 3 21	133 3 28 7 18 N 7 6 9 55	117 6 42 - 23 N 11 4 6 25	51 - 9 5 2 4 8 14	598 31 390 8 98 10 29 3 - 29	861 167 509 3 108 23 37 4 - 10
E.S. CENTRAL Ky. Tenn. Ala. Miss.	21,095 2,424 6,579 6,896 5,196	25,079 2,354 7,850 8,583 6,292	160 6 51 3 100	334 29 70 7 228	43 9 21 11 2	25 14 8 2 1	16 4 7 5	36 18 11 7	36 6 22 5 3
W.S. CENTRAL Ark. La. Okla. Tex.	33,971 3,098 7,848 3,302 19,723	37,653 2,625 9,362 2,593 23,073	165 3 78 3 81	550 7 305 6 232	5 - 2 3 -	20 - 7 2 11	6 1 - 2 3	7 - 1 - 6	61 5 6 - 50
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	6,785 78 53 49 2,054 667 2,677 116 1,091	7,152 28 60 37 2,150 747 2,956 162 1,012	238 1 291 16 11 9 2 6	57 4 3 12 12 13 - 11	40 - 2 4 11 2 11 7 3	26 1 - 9 1 6 5	27 - 1 6 6 6 1 6	11 - 5 3 1 - - 1 1	7 - 1 3 - - 1 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	18,925 2,077 461 15,708 271 408	17,122 1,551 635 14,388 224 324	100 16 12 72 -	136 23 22 89 - 2	52 7 N 41 4	44 14 N 30 -	81 7 3 67 4	96 7 6 81 2 N	82 6 68 2 N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	399 6 U 7	35 361 - U U	- 1 - U -	2 1 - U U	2 U	- 1 - U U	- - - -	N U -	N - U U

# TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,weeks ending September 8, 2001, and September 9, 2000 (36th Week)\*

N: Not notifiable. U: Unavailable. -: No reported cases. \*Incidence data for reporting year 2001 are provisonal and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

					Salmonellosis <sup>†</sup>				
	Mal	aria	Rabie	s, Animal	NE	TSS	Pł	ILIS	
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	
UNITED STATES	780	988	4,267	4,898	22,683	25,703	18,195	22,433	
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	47 4 2 1 16 6 18	51 5 1 22 5 16	477 47 16 47 183 43 141	563 94 9 44 194 40 182	1,582 144 130 52 961 87 208	1,585 93 97 88 942 83 282	1,518 121 120 45 801 114 317	1,651 77 99 92 945 120 318	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	203 45 105 25 28	254 47 138 39 30	855 550 22 136 147	884 569 8 120 187	2,952 819 750 651 732	3,441 806 871 847 917	2,554 816 790 527 421	3,674 921 920 711 1,122	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	74 21 14 25 13	108 15 54 22 12	95 36 1 16 36 6	124 40 19 54 11	3,271 977 354 819 570 551	3,596 888 433 1,133 624 518	2,690 795 310 704 566 315	2,453 1,045 447 1 672 288	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	27 6 5 9 - 2 5	39 13 2 9 2 - 7 6	252 30 62 33 29 25 4 69	423 65 62 38 98 78 1 81	1,471 386 228 425 43 114 105 170	1,655 380 251 497 68 150 262	1,518 474 209 549 59 92 - 135	1,809 494 243 602 58 79 115 218	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	210 1 89 13 41 1 1 5 12 37	216 3 75 13 42 2 21 2 15 43	1,491 25 185 298 107 420 90 224 142	1,684 31 299 409 89 413 113 218 112	5,625 58 583 57 972 85 818 575 873 1,604	5,004 82 549 39 682 113 689 510 852 1,488	3,818 61 603 U 678 92 723 459 884 318	4,123 94 497 U 665 110 767 389 1,239 362	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	22 8 8 4 2	33 11 8 13 1	154 16 87 51	140 18 75 46 1	1,516 241 411 441 423	1,531 261 402 439 429	1,057 143 452 328 134	1,219 191 546 400 82	
W.S. CENTRAL Ark. La. Okla. Tex.	10 3 4 2 1	61 3 10 5 43	510 20 - 48 442	650 20 3 45 582	1,595 499 272 278 546	3,225 453 532 273 1,967	1,297 92 458 236 511	1,956 373 430 211 942	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	35 2 3 - 18 3 3 3 3 3 3	35 1 2 - 18 - 6 4 4	186 31 15 21 11 100 7 1	201 53 9 43 - 17 68 9 2	1,463 50 101 44 406 192 415 155 100	1,871 69 91 516 167 447 341 191	1,080 4 43 360 146 368 136 23	1,828 83 40 510 155 506 358 176	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	152 5 9 129 1 8	191 22 31 128 - 10	247 1 209 37	229 - 7 197 25	3,208 355 171 2,399 28 255	3,795 361 219 3,016 39 160	2,663 491 230 1,701 2 239	3,720 485 274 2,770 25 166	
Guam P.R. V.I. Amer. Samoa C.N.M.I.	3 U	2 4 Ū U	67 Ū	58 U U	405 - U 8	20 436 U U	U U U U U	U U U U U	

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, U	Inited States,
weeks ending September 8, 2001, and September 9, 2000 (36th )	Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. \*Incidence data for reporting year 2001 are provisonal and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date). \*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

	NFT	Shige SS	llosis⁺ P	HUS	Sy (Primary 8	philis Secondary)	Tuberculosis		
Demostin a Anna	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	
UNITED STATES	2001 11.017	2000 15,046	<u>2001</u> 5.227	8.529	<u>2001</u> 3.861	<u>2000</u> 4.173	<u>2001</u> 8.077	9.642	
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	191 6 4 7 136 16 22	285 8 4 3 207 19 44	172 2 2 116 19 31	279 11 7 - 191 25 45	37 1 2 19 7 8	56 1 39 4 11	290 7 11 2 164 24 82	289 12 15 4 170 25 63	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	995 392 265 185 153	1,939 549 789 409 192	582 93 267 157 65	1,248 179 533 344 192	330 18 176 79 57	194 7 82 48 57	1,575 234 811 344 186	1,579 212 844 371 152	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	2,873 2,023 153 281 210 206	3,099 238 1,164 887 554 256	1,331 923 28 204 156 20	884 213 129 2 497 43	668 58 120 194 278 18	879 55 264 303 217 40	873 150 71 428 175 49	930 199 90 434 146 61	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	1,081 286 317 226 20 122 54 56	1,669 541 371 511 12 5 81 148	851 341 261 140 21 59 - 29	1,411 610 261 362 27 3 65 83	51 22 1 11 - 2 15	49 9 10 25 - 2 3	308 160 18 92 3 10 25	348 110 25 134 2 13 13 14 50	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	1,613 7 110 42 211 8 253 204 161 617	1,921 13 137 49 318 4 134 96 177 993	517 7 57 110 8 125 91 91 28	769 16 76 U 246 3 141 71 137 79	1,356 8 162 30 81 - 317 178 230 350	1,375 8 203 29 96 3 361 143 265 267	1,641 9 148 51 172 21 233 134 299 574	1,966 14 176 19 190 21 263 188 430 665	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	942 344 71 176 351	681 247 254 39 141	400 175 75 124 26	377 52 289 31 5	422 31 228 83 80	603 59 365 84 95	523 78 199 175 71	636 70 254 205 107	
W.S. CENTRAL Ark. La. Okla. Tex.	1,069 420 114 32 503	2,409 150 202 78 1,979	714 155 132 15 412	745 43 128 31 543	478 26 100 48 304	569 75 156 83 255	712 100 - 100 512	1,440 143 135 110 1,052	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	653 2 25 3 157 85 284 44 53	737 7 41 5 137 97 294 57 99	372 - 140 45 137 41 8	536 25 3 109 64 204 65 66	170 - 1 31 16 111 7 4	157 - 1 7 13 130 1 4	309 6 8 2 78 21 119 24 51	348 10 2 57 30 139 32 72	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,600 142 59 1,346 4 49	2,306 346 123 1,803 7 27	288 167 74 1 46	2,280 328 82 1,843 3 24	349 37 8 296 - 8	291 48 10 232 - 1	1,846 167 75 1,475 31 98	2,106 170 65 1,701 76 94	
Guam P.R. V.I. Amer. Samoa C.N.M.I.	- 8 - U 4	34 26 - U U		U U U U U	172 U	3 120 - U U	- 76 - U 20	38 109 - U U	

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United Stat	tes,
weeks ending September 8, 2001, and September 9, 2000 (36th Week)*	-

Not notifiable. U: Unavailable. -: No reported cases. \*Incidence data for reporting year 2001 are provisonal and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date). Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

	H. influ	ienzae,	н	Hepatitis (Viral), By Type Measles (Rubeola)					Measles (Rubeola)				
	Inva	sive	A		В		Indige	nous	Impo	Imported <sup>†</sup> Total			
Reporting Area	Cum. 2001 <sup>§</sup>	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	2001	Cum. 2001	2001	Cum. 2001	Cum. 2001	Cum. 2000	
UNITED STATES	953	892	6,587	8,914	4,427	4,735	-	47	-	42	89	65	
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn	58 1 3 34 3 13	67 1 12 5 32 2 15	376 8 12 8 151 26 171	271 14 18 8 104 16 111	61 5 11 4 - 17 24	77 5 12 6 10 14 30	- - - - -	4 - 1 2 - 1	- - - - -	1 - - 1 -	5 - 1 3 - 1	6 - 3 - - -	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	137 53 36 32 16	168 68 47 31 22	677 173 209 159 136	994 154 341 193 306	674 94 322 64 194	830 87 409 130 204	- - - -	4 1 2 - 1	- - - -	11 4 1 1 5	15 5 3 1 6	21 10 10 - 1	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	126 53 37 10 7 19	140 42 25 47 9 17	693 166 63 192 230 42	1,178 199 57 520 336 66	639 83 35 100 421	498 78 36 84 277 23	- - - -			10 3 4 3 -	10 3 4 3 -	7 2 3 2 -	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	49 28 - 13 6 - 1 1	49 24 - 16 2 - 3 4	284 24 26 77 2 2 28 125	549 154 56 227 2 1 24 85	130 13 16 68 - 1 17 15	208 27 21 106 2 1 31 20	- - - U - -	4 2 - - - - -	- - - - - - -		4 2 - - - - - -	1 - - - - -	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	275 64 - 20 10 41 5 68 67	202 57 - 32 5 19 7 52 30	1,551 - 33 94 9 132 61 609 423	940 10 131 20 107 49 111 44 180 288	917 95 11 115 20 133 24 223 296	817 10 90 27 105 10 165 11 142 257	U U - - - U	4 - 1 - - 1	U U - - - U	1 - - - - - -	5 - 3 - 1 - - 1 -	2 - - 2 - - - -	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	61 2 31 26 2	38 12 16 8 2	266 84 105 63 14	313 40 111 43 119	304 31 159 61 53	333 61 159 35 78	- - - -	2 2 - -	- - - -	- - - -	2 2 - -	- - -	
W.S. CENTRAL Ark. La. Okla. Tex.	35 - 3 32 -	54 2 15 35 2	638 55 54 96 433	1,720 111 62 192 1,355	466 67 30 70 299	719 72 107 107 433	- U U -	1 - - 1	- U U -	- - - -	1 - - 1		
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	129 - 1 7 29 15 51 6 10	87 1 3 1 20 18 34 7 3	586 9 50 25 61 29 305 61 46	639 5 19 4 142 59 323 40 47	406 2 10 31 79 114 115 23 32	363 4 57 108 138 17 32	- - - - - - - - - - U		- - - - - - - - - - -	1 - - - - - - -	1 - - - - - - -	12 - - 2 - 3 7	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	83 2 17 35 6 23	87 5 24 30 6 22	1,516 93 63 1,345 14 1	2,310 206 141 1,939 11 13	830 96 71 640 8 15	890 72 77 722 9 10	- - - -	28 13 3 10 - 2	- - - -	18 2 - 11 5	46 15 3 21 7	16 3 - 9 1 3	
Guam P.R. V.I. Amer. Samoa C.N.M.I.	1 - U	1 3 - U U	- 75 - U	1 196 - U U	127 - U 26	9 196 - U U	U U U U U	- - U	U U U U U	- - U -	- U	2 - U U	

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 8, 2001, and September 9, 2000 (36th Week)\*

N: Not notifiable.
U: Unavailable.
-: No reported cases.
\*Incidence data for reporting year 2001 are provisonal and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

\* For imported measles, cases include only those resulting from importation from other countries.
\* Of 197 cases among children aged <5 years, serotype was reported for 97, and of those, 17 were type b.

	Mening Dis	jococcal ease	Mumps				Pertussis			Rubella			
Reporting Area	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000		
UNITED STATES	1,582	1,573	2	153	251	34	3,067	4,372	-	17	109		
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	85 1 10 5 48 3 18	94 8 9 2 54 8 13	- U - -		4 - - 1 1 2	- U - - -	275 25 25 206 5 14	1,129 31 82 175 790 14 37	- U - - -		12 - 2 - 8 1 1		
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	166 46 31 39 50	178 48 35 33 62	- - -	17 3 9 2 3	20 7 6 3 4	1 1 - -	220 118 34 13 55	398 184 58 30 126	- - -	5 1 3 1 -	9 1 8 - -		
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	206 72 29 22 47 36	272 64 32 68 78 30		14 1 10 2 -	19 7 1 6 4 1	4 - 4 - -	391 217 50 42 40 42	508 237 68 57 55 91	- - - -	3 - 1 2 - -	1 - - 1 -		
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	107 16 21 39 5 5 10 11	109 17 22 51 2 5 5 7	- - - - - - -	8 3 - - - 1 4	14 - 6 4 - 1 3	12 12 - - U - -	180 70 17 70 - 3 4 16	323 189 39 49 3 3 9 31	- - - - - - - - -	3 - 1 - - 1	1 - - - 1 -		
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	301 3 35 31 11 58 31 36 96	224 22 35 10 32 18 38 69	1 U 1 - - - U	27 5 - 3 2 7 4	37 - 8 - 8 - 5 10 2 4	3 U 3 U - - - U	167 25 1 31 25 51 26 7 24	328 8 80 3 58 1 76 23 27 52	U U - - - U	4 - - - 2 - 2	60 - - 52 6 - 2		
E.S. CENTRAL Ky. Tenn. Ala. Miss.	103 18 44 30 11	110 24 45 30 11		3 1 - 2	4 - 2 2 -	1 1 - -	87 19 38 27 3	90 45 25 17 3	- - -		5 1 1 3		
W.S. CENTRAL Ark. La. Okla. Tex.	176 16 56 24 80	167 11 38 22 96	- U U -	9 1 2 - 6	26 1 5 20	3 1 U U 2	255 12 2 1 240	233 31 17 15 170	- U U -		7 1 1 5		
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	76 3 7 6 27 11 11 7 4	71 4 6 23 6 22 7 3	- - - - - - U	9 1 1 2 1 1 1	16 1 - 1 4 4 5	7 - - - - - - - - -	1,050 21 166 2 205 97 491 57 11	518 32 47 3 284 77 51 15 9	- - - - - - U - - - U	1 - - 1 - - - -	2 - - 1 - 1 - -		
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	362 53 31 265 2 11	348 37 46 251 6 8	1 - N - 1	66 1 29 1 35	111 5 N 78 8 20	3 - - - -	442 107 35 268 3 29	845 259 92 444 18 32	- - - -	1 - - - 1	12 7 5 -		
Guam P.R. V.I. Amer. Samoa C.N.M.I.	- 4 - U -	- 8 - U U	U U U U	- - - U	12 - - U U	U U U U U	2 - U	3 6 - U U	U U U U U	- - U	1 - - U U		

# TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 8, 2001, and September 9, 2000 (36th Week)\*

N: Not notifiable. U: Unavailable. - : No reported cases. \*Incidence data for reporting year 2001 are provisonal and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

	All Causes, By Age (Years)						P&I <sup>†</sup>			All Cau	ses, By	Age (Y	ears)		D9.1†
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn. Cambridge, Mass. Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Mas. New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass	360 U 23 18 U 57 27 10 55. 35 48 6 31	252 U 16 15 U 30 18 8 24 24 24 34 6 24	61 U 6 1 U 12 5 1 8 4 9 -	29 U 1 2 U 9 4 - 2 5 - 2	9 U - U 1 - 2 3 -	9 U - U 5 - 1 - 2 - 1	25 U 3 · U 5 2 2 3 2 · · 2	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, F Tampa, Fla. Washington, D.C Wilmington, Del	863 U 117 93 118 62 53 47 58 147 58 148 2. 148 2. 101 34	547 U 72 71 34 32 29 39 22 101 61 34	182 U 26 31 15 8 10 12 8 24 29	83 U 13 12 9 10 6 5 - 15 7 -	26 U 34 32 3 1 2 1 5 2	24 U 3 6 4 1 4 1 3 1 3	50 U 15 8 4 2 2 3 - 4 4 -
Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§ Jersey City, N.J. New York City, N.J. New York City, N.J. New York City, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J.	24 46 2,101 16 102 33 24 41 43 24 41 43 24 41 43 36 36 116 116 23 21 81 91 91	20 33 1,464 38 75 21 18 31 24 692 0 0 317 22 10 85 21 65 21 65 21 165	3 8 415 11 2 16 4 6 7 13 210 U 100 9 2 17 2 3 10 3 1 2 3 10 3	1 3 151 2 - 7 4 - 2 5 76 U U 31 5 3 10 - 1 3 2 - 2 - 2 - 2 - 2 - 2 - 7 6 - 2 - 7 6 - 2 - 7 6 - 2 - 7 6 - 2 - 7 - 7 - 7 - 2 - 7 - 7 - 7 - 7 - 7	2 36 2 - - 1 14 U U 12 - 1 4 -	31 1 4 2 1 16 U 4 - - - 3	33 953 · 9212 · 35UU4215218 · 1	E.S. CENTRAL Birmingham, Ala Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Al Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, T Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te	763 a. 149 nn. 68 54 191 75 a. 32 108 1,089 74 ex. 40 172 51 94 311 0 4 x. 172 2 94	513 108 55 61 32 115 57 96 65 548 35 30 83 31 53 16 U U 212 20 122	169 30 8 13 50 9 8 33 254 19 6 9 56 15 21 8 U U 38 6 U U 38 6	47 6 1 6 6 6 6 16 5 3 4 10 9 4 5 - 19 3 12 5 U 13 4 U 13 4	14 3 1 1 2 4 2 1 - 42 1 2 - 6 2 2 3 U U 4 -	20 2 3 - 1 6 2 1 5 29 2 - 1 3 - 6 11 U U 5 -	54 12 6 3 2 13 2 4 12 5 4 2 3 13 2 1 2 U U 7 3
Utica, N.Y. Yonkers, N.Y. E.N. CENTRAL Akron, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Cleveland, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Garand Rapids, Mid Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohio W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans. Kansas City, Mo.	U 1,461 38 U 94 107 157 116 175 37 48 187 175 37 48 187 37 48 187 37 48 187 537 48 556 40 37 5539 62 37 571 29	UU 9839330 300 59980 977333 889 101133 28840 103328 40 103328 380 511 360 511 277 380 380 511 277 277 277 277 277 277 277 277 277 2	UU 3056U172039171559384642056151710 99682158	UU 93 2 2 U1 6 11 4 13 2 4 4 4 16 - 3 1 3 1 4 2 31 1 - 1 10 -	UU 371 - U3161532327 - 2 - 1 19122	UU 391 - U4 - 4555 74 - 32 - 211 103 3	UU 8634U4565822.5834.1.51 3741.51	<ul> <li>Julsa, Okla.</li> <li>MOUNTAIN</li> <li>Albuquerque, N</li> <li>Boise, Idaho</li> <li>Colo. Springs, C</li> <li>Denver, Colo.</li> <li>Las Vegas, Nev.</li> <li>Ogden, Utah</li> <li>Phoenix, Ariz.</li> <li>Pueblo, Colo.</li> <li>Salt Lake City, U</li> <li>Tucson, Ariz.</li> <li>PACIFIC</li> <li>Berkeley, Calif.</li> <li>Fresno, Calif.</li> <li>Glendale, Calif.</li> <li>Honolulu, Hawa</li> <li>Long Beach, Cali</li> <li>Los Angeles, Cal</li> <li>Pasadena, Calif.</li> <li>San Diego, Calif.</li> <li>San Diego, Calif.</li> <li>Sant Cruz, Calif.</li> <li>Santa Cruz, Wash.</li> <li>Spokane, Wash.</li> </ul>	38 929 929 925 olo. 43 99 231 37 150 28 tah 94 1,384 10 44 1,384 10 44 10 11 10 11 10 10 10 10 10 10	236 6287 1830664 164 24937 1648 9777 32156 70219 80367 219 80367 219 80367 219 80367 225529	5 15 18 20 7 8 14 46 7 3 8 18 30 25 3 2 4 6 6 13 17 15 3 U 30 29 4 18 9 29 3 29 3	44 7210 - 51112416347 8716 - 24262U97776191	271 - 4825 - 61 31 - 2 - 110 - U4224122	1 12 4 1 - 4 - 2 1 22 1 1 3 - 6 - U 1 3 5 2 - 1 - 1 - 1 3 5 2 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	33 6413 2 3 4 18 2 10 1 8 3 93 1 4 1 9 6 18 4 U 10 7 7 11 2 3 5
Minneapolis, Min Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	n. 96 72 75 79 13	73 53 42 62 9	18 12 19 9 2	3 5 8 2 1	- 2 5 5 1	2 - 1 1 -	11 8 - 7 -	Tacoma, Wash. TOTAL	92 9,489¶	68 6,405	15 1,925	6 702	1 241	- 196	5 534

TABLE IV. Deaths in 122 U.S. cities,\* week endingSeptember 8, 2001 (36th Week)

U: Unavailable. -:No reported cases. \*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. <sup>1</sup> Pneumonia and influenza. <sup>8</sup> Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. <sup>9</sup> Total includes unknown ages.

Weekly Notifiable Disease Morbidity	Data and 122 Cities Mortality Data
Samuel L. Groseclos Wayne S. B	se, D.V.M., M.P.H. rathwaite
State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Jim Vaughan Carol A. Worsham	<i>CDC Operations Team</i> Carol M. Knowles Deborah A. Adams Willie J. Anderson Lateka M. Dammond Patsy A. Hall Mechele A. Hester Felicia J. Connor Pearl Sharp
le ferrer	

All MMWR references are available on the Internet at <http://www.cdc.gov/mmwr/>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H. Deputy Director for Science and	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane	
	Editor, <i>MMWR</i> Series John W. Ward, M.D.	David C. Johnson	
Public Health, Centers for Disease Control and Prevention	Acting Editor, <i>MMWR</i> Series Terrence L. Chorba, M.D., M.P.H.	Desktop Publishing Lynda G. Cupell Morio M. Hinging	
David W. Fleming, W.D.	Acting Managing Editor, <i>MMWR</i> (Weekly Teresa F. Rutledge	/)	
☆U.S. Government Printing Office: 2001-633-173/49009 Region IV			